AndreaBozzo/ceres-open-data-index huggingface dataset:
Cancer Mapping Data: 2005-2009

The Cancer Mapping data consists of counts of newly diagnosed cancer among New York State residents and is in response to legislation regarding "Cancer incidence and environmental facility maps" signed into law in 2010 (Public Health Law §2401-B). The law specifies the publication of maps showing cancer counts for small geographic areas along with certain facilities regulated by the State Department of Environmental Conservation. The official web site is called Environmental Facilities and Cancer Mapping.

The dataset is ONLY for the cancer-related data fields on the Environmental Facilities and Cancer Mapping web site.  This dataset includes observed counts for 23 separate anatomical sites at the level of census block group. Block groups are small geographic areas typically averaging 1,000 to 1,500 people. To protect confidentiality, each area contains a minimum of 6 total cancers among males and 6 total cancers among females.

For more information, check out http://www.health.ny.gov/statistics/cancer/registry/about.htm.
Compound 527527: Propanoic acid, 2-chloro, undecyl ester

Chemical compound data from PubChem database. IUPAC Name: undecyl 2-chloropropanoate. Molecular Formula: C14H27ClO2. Molecular Weight: 262.81. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
NYTD Reviewer Recruitment Postcard for Young People

This young-person-friendly postcard, developed in collaboration with National Youth in Transition Database (NYTD) Reviewers, provides recruitment details and information to prospective NYTD Reviewers about what to expect from participation in the NYTD Reviews.

If you are interested in learning more about becoming a NYTD Reviewer, please email the Child Welfare Compliance Reviews Team at cw-mail@jbsinternational.com for additional information, or check out NYTD Reviewer Responsibilities at https://www.acf.hhs.gov/cb/report/nytd-reviewer-responsibilities.

Metadata-only record linking to the original dataset. Open original dataset below.
Patent AT-E4009-T1: [Translated] ALL-METAL THERMAL INSULATION, CONSISTING OF JOINTABLE THERMAL INSULATION COMPONENTS.

All-metal heat insulation, including building blocks which can be joined together, the building blocks each including metallic foils being thermally movably supported and mutually spaced apart from each other forming insulating cells therebetween, spacer strips for maintaining the mutual spacing between the foils, and at least two housing plates at least partly surrounding the foils and spacer strips and being disposed at a given distance from each other, the spacer strips being adjacent to each other and being fastened to at least one of the housing plates, the spacer strips being mutually spaced apart from each other at a distance at least equal to the thickness of one foil forming receiving pockets for the foils at least at one of the plates, the foils being shorter than the given distance between the housing plates and being slideably fitted in the receiving pockets.
2006 NSDUH Detailed Tables

These are the 2006 NSDUH national detailed tables with the following sections:Illicit Drug Use Tables - 1.1 to 1.92Tobacco Product and Alcohol Use Tables - 2.1 to 2.84Risk and Protective Factors Tables - 3.1 to 3.24Incidence Tables - 4.1 to 4.16Dependence, Abuse, and Treatment Tables - 5.1 to 5.56Mental Health Tables - 6.1 to 6.41Miscellaneous Tables - 7.1 to 7.93Trend Tables - 8.1 to 8.46Sample Size and Population Estimates Tables - 9.1 to 9.13
Compound 525790: N-(3-Chlorophenyl)-N'-(3-bromophenyl)formamidine

Chemical compound data from PubChem database. IUPAC Name: N'-(3-bromophenyl)-N-(3-chlorophenyl)methanimidamide. Molecular Formula: C13H10BrClN2. Molecular Weight: 309.59. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Hawaii (HI)

This report uses 2008 to 2010 National Survey on Drug Use and Health (NSDUH) to assess past year alcohol use disorder and illicit drug use disorder among persons aged 12 or older for Hawaii overall and for substate regions within Hawaii. Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE).
Guide To P-Value Tables

Substate estimates for these years are no longer available due to methodological concerns with combining 2020 data with data from 2018 and 2019. We apologize for any inconvenience or confusion this may cause.Because of the COVID-19 pandemic, most respondents answered the survey via the web in Quarter 4 of 2020, even though all responses in Quarter 1 were from in-person interviews. It is known that people may respond to the survey differently while taking it online, thus introducing what is called a mode effect.When the state estimates were released, it was assumed that the mode effect was similar for different groups of people. However, later analyses have shown that this assumption should not be made. Because of these analyses, along with concerns about the rapid societal changes in 2020, it was determined that averages across the three years could be misleading.For more detail on this decision, see the 2018-2020substate data page.
Connecticut (CT)

This report presents Connecticut\'s estimates for 25 measures of substance use and mental health based on the combined 2009 and 2010 National Surveys on Drug Use and Health (NSDUHs). Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE). Resuts are provided for Connecticut for five age groups: 12 to 17, 18 to 25, 26 or older, 18 or older and all persons 12 or older.
Commentary on "Genetic linkage and transmission disequilibrium of marker haplotypes at chromosome 1q41 in human systemic lupus erythematosus", by RR Graham

Genome-wide linkage analysis studies in families with systemic lupus erythematosus (SLE) have revealed consistent evidence of linkage to several regions of the genome. In a previous issue of this journal, Graham and colleagues described their approach to following up the linkage data for one of these regions, 1q41–42. Using methods based on the transmission disequilibrium test, the region likely to harbour a SLE disease gene was refined to 2.3 Mb. This commentary discusses their approach and identifies lessons that may be applicable to the investigation of other complex diseases.
Omeprazole magnesium

Omeprazole Magnesium is an over-the-counter proton pump inhibitor available as a 20 mg delayed-release oral capsule. It helps reduce stomach acid to treat frequent heartburn, acid reflux, and related conditions. Manufactured by companies like CVS and Walmart under brands such as Omeprazole or Equate. This information was generated using AI and is provided for informational and research purposes only.
Hepatic glucokinase promoter polymorphism is associated with hepatic insulin resistance in Asian Indians.

Background
          The role of glucokinase (GCK) in the pathogenesis of maturity-onset diabetes of the young is well established. However, its role in the common form of type 2 diabetes is far from convincing. We investigated the role of the G-to-A polymorphism in the hepatic GCK promoter on insulin sensitivity and beta cell function in 63 normotensive Asian Indians with normal glucose tolerance. As proposed by Matsuda and DeFronzo, hepatic insulin sensitivity (ISIH) and total body insulin sensitivity (ISIM) were estimated from the oral glucose tolerance test. Beta cell function was estimated using %B from the Homeostasis Model Assessment and insulingenic index (dI/dG).
        
        
          Result
          We identified 38 GG, 24 GA, and one AA subjects. The AA subject was pooled with the GA subjects during the analysis. No difference was noted in the demographic features between the two genotypic groups (GG vs. GA/AA). Compared to the GG group, the GA/AA group had a lower ISIH (p=0.002), a lower ISIM (p=0.009), a higher %B (p=0.014), and a higher dI/dG (p=0.030). Multivariate analysis revealed that this polymorphism is an independent determinant for ISIH (p=0.019) and along with age, waist-hip ratio, gender, and diastolic blood pressure accounted for 51.5% of the variation of ISIH. However, this polymorphism was a weak, but independent determinant for ISIM (p=0.089) and %B (p=0.083). Furthermore, it had no independent effect on dI/dG (p=0.135).
        
        
          Conclusions
          These data suggest that the G-to-A polymorphism in the hepatic GCK promoter is associated with hepatic insulin resistance in Asian Indians.
Patent AT-E401348-T1: [Translated] IMMUNOCONJUGATES WITH HIGH BINDING AFFINITY

Mesothelin is a differentiation antigen present on the surface of ovarian cancers, mesotheliomas and several other types of human cancers. Because among normal tissues mesothelin is only present on mesothelial cells, it represents a good target for antibody mediated delivery of cytotoxic agents. The present invention is directed to anti-mesothelin antibodies, including Fv molecules with particularly high affinity for mesothelin, and immunoconjugates employing them. Also described are diagnostic and therapeutic methods using the antibodies. The anti-mesothelin antibodies are well-suited for the diagnosis and treatment of cancers of the ovary, stomach, squamous cells, mesotheliomas and other malignant cells expressing mesothelin.
Phoenix: Drug-Related Emergency Department Visits, 2004-2011 - Accidental Ingestions

Excel file with estimates, rates, relative standard errors, trends and confidence intervals, covering 2004-2011 for emergency department visits involving accidental ingestions in the Phoenix metropolitan area. This analytic category includes ED visits in which an individual accidentally or unknowingly used or was administered a prescription drug, over-the-counter medication, or dietary supplement. Drug-related accidental ingestion typically involves patients aged 5 and under.  This analytic category does not include drug misuse or abuse.File includes data for over 500 drugs, including illicit drugs, prescription and over-the-counter medications, dietary supplements, inhalants and alcohol.  Includes total visits, gender, age group, race/ethnicity, outcome of visit, drug combinations, number of drugs involved in visit, drug frequency, and drugs confirmed by toxicology.Additional detail is provided for illicit drugs, psychotherapeutic drugs, central nervous system (CNS) drugs, respiratory drugs and cardiovascular drugs.
Systematic adjudication of myocardial infarction end-points in an international clinical trial

Background
          Clinical events committees (CEC) are used routinely to adjudicate suspected end-points in cardiovascular trials, but little information has been published about the various processes used. We reviewed results of the CEC process used to identify and adjudicate suspected end-point (post-enrolment) myocardial infarction (MI) in the large Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin (Eptifibatide) Therapy (PURSUIT) trial.
        
        
          Methods
          The PURSUIT trial randomised 10,948 patients with acute coronary syndromes to receive eptifibatide or placebo. A central adjudication process was established prospectively to identify all suspected MIs and adjudicate events based on protocol definitions of MI. Suspected MIs were identified by systematic review of data collection forms, cardiac enzyme results, and electrocardiograms. Two physicians independently reviewed all suspected events. If they disagreed whether a MI had occurred, a committee of cardiologists adjudicated the case.
        
        
          Results
          The CEC identified 5005 patients with suspected infarction (46%), of which 1415 (28%) were adjudicated as end-point infarctions. As expected, the process identified more end-point events than did the site investigators. Absolute and relative treatment effects of eptifibatide were smaller when using CEC-determined MI rates rather than site investigator-determined rates. The site-investigator reporting of MI and the CEC assessment of MI disagreed in 20% of the cases reviewed by the CEC.
        
        
          Conclusions
          End-point adjudication by a CEC is important, to provide standardised, systematic, independent, and unbiased assessment of end-points, particularly in trials that span geographic regions and clinical practice settings. Understanding the CEC process used is important in the interpretation of trial results and event rates.
Compound 527305: 3-(3-Butyloxiran-2-yl)prop-2-enal

Chemical compound data from PubChem database. IUPAC Name: 3-(3-butyloxiran-2-yl)prop-2-enal. Molecular Formula: C9H14O2. Molecular Weight: 154.21. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 528370: Nornicotine, N-hexanoyl

Chemical compound data from PubChem database. IUPAC Name: 1-(2-pyridin-3-ylpyrrolidin-1-yl)hexan-1-one. Molecular Formula: C15H22N2O. Molecular Weight: 246.35. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 526243: 1,2,4,7-Tetrabromo-dibenzofuran

Chemical compound data from PubChem database. IUPAC Name: 1,2,4,7-tetrabromodibenzofuran. Molecular Formula: C12H4Br4O. Molecular Weight: 483.77. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Virginia (VA)

This report uses 2008 to 2010 National Survey on Drug Use and Health (NSDUH) to assess past year alcohol use disorder and illicit drug use disorder among persons aged 12 or older for Virginia overall and for substate regions within Virginia. Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE).
Patent AT-E401228-T1: [Translated] PUSH CAR

A stroller (1) comprising at least one front wheel (14) and at least one rear wheel (24), which wheels are interconnected by means of a collapsible folding mechanism. The stroller furthermore comprises a rod (2,3) fitted with a handle (4,5), which is connected to the folding mechanism, the stroller being foldable from an erect position to a collapsed position, and vice versa. The folding mechanism comprises a linkage system having at least one central portion (21,51,121,160) as well as a number of rods (22,23,19,20) extending from said central portion. The ends of the rods remote from said central portion (21) are connected to said at least one rear wheel (24) and to the rods fitted with the handle (2,3), respectively. The central portion (21,51,121,160) is movable from and to a support (13,113,61,155) connected to said at least one front wheel over an axis (30,60,130) extending between the central portion and the support. <IMAGE>
Compound 529210: Trimethylsilyl cyclobutanecarboxylate

Chemical compound data from PubChem database. IUPAC Name: trimethylsilyl cyclobutanecarboxylate. Molecular Formula: C8H16O2Si. Molecular Weight: 172.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 526992: 2,2-Dimethyl-4-pentyl-1,3-dioxane

Chemical compound data from PubChem database. IUPAC Name: 2,2-dimethyl-4-pentyl-1,3-dioxane. Molecular Formula: C11H22O2. Molecular Weight: 186.29. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 525610: N,N-Dimethyl-N'-benzyl-benzamidine

Chemical compound data from PubChem database. IUPAC Name: N'-benzyl-N,N-dimethylbenzenecarboximidamide. Molecular Formula: C16H18N2. Molecular Weight: 238.33. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E400860-T1: [Translated] MOTOR VEHICLE INFRARED (IR) COMMUNICATION DEVICE

A motor vehicle infrared (IR) communication device ( 2 ) for an electronic fee-charging system, comprising IR transmitting and receiving elements ( 9 ) arranged in a housing ( 4 ) and oriented according to a first direction ( 10 ), which first direction ( 10 ) extends at least substantially in a vertical longitudinal plane of the motor vehicle when the communication device ( 2 ) is in a state installed in a motor vehicle, and transmitting and receiving electronics ( 36, 37 ); further IR elements ( 13 ) oriented at least according to a second direction ( 14 ) are additionally arranged in the housing ( 4 ), this second direction ( 14 ) being oriented towards a side, relative to the first direction ( 10 ), or to the vertical longitudinal plane, respectively.
NNDSS - TABLE 1Z. Pertussis to Poliomyelitis, paralytic

NNDSS - TABLE 1Z. Pertussis to Poliomyelitis, paralytic - 2019. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents. 

Note: 
This table contains provisional cases of national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up. Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html. 

Footnotes:
U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.
-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.
NN: Not nationally notifiable — This condition was not designated as being nationally notifiable.
NP: Nationally notifiable but not published — CDC does not have data because of changes in how conditions are categorized.
Cum: Cumulative year-to-date counts.
Max: Maximum — Maximum case count during the previous 52 weeks.
* Case counts for reporting years 2018 and 2019 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the US, a US territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-US Residents' category. For further information on interpretation of these data, see https://wwwn.cdc.gov/nndss/document/Users_guide_WONDER_tables_cleared_final.pdf. 
† Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).
NCHS - Teen Birth Rates for Females by Age Group, Race, and Hispanic Origin: United States

This dataset includes teen birth rates for females by age group, race, and Hispanic origin in the United States since 1960. 

Data availability varies by race and ethnicity groups. All birth data by race before 1980 are based on race of the child. Since 1980, birth data by race are based on race of the mother. For race, data are available for Black and White births since 1960, and for American Indians/Alaska Native and Asian/Pacific Islander births since 1980. Data on Hispanic origin are available since 1989. Teen birth rates for specific racial and ethnic categories are also available since 1989. From 2003 through 2015, the birth data by race were based on the “bridged” race categories (5). Starting in 2016, the race categories for reporting birth data changed; the new race and Hispanic origin categories are: Non-Hispanic, Single Race White; Non-Hispanic, Single Race Black; Non-Hispanic, Single Race American Indian/Alaska Native; Non-Hispanic, Single Race Asian; and, Non-Hispanic, Single Race Native Hawaiian/Pacific Islander (5,6). Birth data by the prior, “bridged” race (and Hispanic origin) categories are included through 2018 for comparison.

National data on births by Hispanic origin exclude data for Louisiana, New Hampshire, and Oklahoma in 1989; New Hampshire and Oklahoma in 1990; and New Hampshire in 1991 and 1992. Birth and fertility rates for the Central and South American population includes other and unknown Hispanic. Information on reporting Hispanic origin is detailed in the Technical Appendix for the 1999 public-use natality data file (see ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/DVS/natality/Nat1999doc.pdf).
Compound 529327: Furan-2-carboxaldehyde, 3,5-dimethyl

Chemical compound data from PubChem database. IUPAC Name: 2,4-dimethylcyclopenta-1,3-diene-1-carbaldehyde. Molecular Formula: C8H10O. Molecular Weight: 122.16. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E400517-T1: [Translated] PRESSURE CAN WITH INNER SLEEVE

The invention relates to a pressurized can comprising a body, a valve arranged in a dome, a base (16), an inner shell (1) with detachable, push-off type cover (8) arranged on the base (16) and a movable shaft (7) arranged in a fixing element (2) and extending through the base (16) into the inner shell (1) and serving as release element for the inner shell with the inner shell (1) being connected to the base (16) via the fixing element (2), moreover comprising a piston element (3) movable in longitudinal direction of the inner shell (1) and being arranged inside the inner shell (1), the piston element yielding a sealing effect at the inner shell's (1) inner wall and interacting with the shaft (7) in such a manner that when the shaft (7) is moved into the inner shell (1) the piston element (3) causes a liquid present inside the inner shell (1) to be pressurized so that the cover (8) is forced off.
Drug Abuse Warning Network (DAWN): Findings From Drug-Related Emergency Department Visits, 2022

An analysis of the 2022 DAWN data presents:(1) nationally representative weighted estimates of all drug-related emergency department (ED) visits, (2) nationally representative weighted estimates of the top substances involved in drug-related ED visits, including rates by race and ethnicity; (3) nationally representative weighted estimates of opioid-related ED visits by type of opioid, (4) drugs involved in polysubstance ED visits, and (5) the identification of newly mentioned drugs in 2022.Clickhereto view the 2022 report.